CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $281 | -88.7% | 5 | -90.9% | 0.00% | – |
| Q1 2023 | $2,488 | +11.3% | 55 | 0.0% | 0.00% | – |
| Q4 2022 | $2,236 | -44.1% | 55 | 0.0% | 0.00% | -100.0% |
| Q3 2022 | $4,000 | +33.3% | 55 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $3,000 | 0.0% | 55 | 0.0% | 0.00% | – |
| Q1 2022 | $3,000 | -25.0% | 55 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $4,000 | -33.3% | 55 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $6,000 | -33.3% | 55 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $9,000 | +28.6% | 55 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $7,000 | -22.2% | 55 | -6.8% | 0.00% | -50.0% |
| Q4 2020 | $9,000 | +80.0% | 59 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $5,000 | +25.0% | 59 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $4,000 | +100.0% | 59 | +47.5% | 0.00% | 0.0% |
| Q1 2020 | $2,000 | -50.0% | 40 | -60.0% | 0.00% | 0.0% |
| Q3 2018 | $4,000 | -33.3% | 100 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $6,000 | +20.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $5,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |